Drug intelligence / Profile preview

MDH-212

Development stage: Preclinical
Lead developer: MD Healthcare
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

MDH-212 is a preclinical-stage microbial extracellular vesicle (EV)-based therapeutic being developed by MD Healthcare. It is designed for the treatment of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and coronary artery disease (CHD). The therapeutic utilizes MD Healthcare's proprietary microbial EV platform, which leverages naturally released, lipid bilayer-delimited nanoparticles from commensal bacteria to deliver therapeutic cargo and modulate host immune and metabolic pathways. MDH-212 is currently undergoing IND-enabling studies, with Phase 1 clinical trials planned to initiate in late 2027.

Beyond the preview

Go deeper on MDH-212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDH-212.

Explore the full profile